C. Burns

发表

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

R. Henry, A. Baron, J. Frias, 2018, PloS one.

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

L. Aronne, C. Weyer, A. Halseth, 2008, Diabetes Care.

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

K. Fujioka, L. Aronne, C. Weyer, 2007, The Journal of clinical endocrinology and metabolism.

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

C. Weyer, J. Blundell, Steven R Smith, 2007, American journal of physiology. Endocrinology and metabolism.

Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects

S. Doran, J. Wishart, M. Horowitz, 2007, Obesity.

Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration

D. Revicki, H. Jinnah, W. Lenderking, 2019, Orphanet Journal of Rare Diseases.

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes. Diabetes Care 2013;36:4022–4029

F. Greenway, K. Fujioka, R. Plodkowski, 2014, Diabetes Care.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

R. DeFronzo, J. Rosenstock, J. Buse, 2015, Diabetes Care.

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

S. Doran, J. Wishart, M. Horowitz, 2005, Diabetologia.

Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase–Associated Neurodegeneration

A. Lang, R. Jech, Nora Vanegas-Arroyave, 2020, Movement disorders : official journal of the Movement Disorder Society.

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

F. Greenway, K. Fujioka, R. Plodkowski, 2013, Diabetes Care.

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

R. DeFronzo, J. Buse, A. Baron, 2016, Diabetologia.

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)

Dennis D. Kim, E. Dunayevich, C. Apovian, 2013, Obesity.

Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial

L. Aronne, Larry Z. Shen, A. Halseth, 2010, Obesity.

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study

Dennis D. Kim, E. Dunayevich, S. McElroy, 2013, The primary care companion for CNS disorders.